Please select the option that best describes you:

Do you prefer CDK 4/6 inhibitor or PARP inhibitor as first line treatment in a patient with HR+/HER2 neg relapsed/metastatic BRCA positive breast cancer who had previous adjuvant chemotherapy and developed metastatic recurrence while on AI?  



Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at Aspirus UW Cancer Center
In managing this patient, it would be helpful to k...
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution
Sign in or Register to read more

Answer from: Medical Oncologist at Community Practice
Sign in or Register to read more

Answer from: Medical Oncologist at Community Practice
Sign in or Register to read more

Answer from: Medical Oncologist at Community Practice
Sign in or Register to read more